Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Steviol glycosides, the primary sweetening compounds extracted from the leaves of Stevia rebaudiana, have attracted scientific interest due to their potential benefits for individuals with Metabolic Syndrome. Several studies have explored steviol glycosides as non-nutritive sweeteners that do not raise blood glucose levels, which is relevant for components of Metabolic Syndrome such as hyperglycemia and insulin resistance. Clinical trials have demonstrated that replacing caloric sweeteners with stevia can help reduce overall caloric intake, which may indirectly support weight management and glycemic control. A few small studies and animal experiments suggest that steviol glycosides might improve insulin sensitivity or reduce blood pressure, both of which are relevant to Metabolic Syndrome. However, the evidence is mixed and often based on short-term interventions or surrogate endpoints, rather than robust, long-term clinical outcomes.

Current scientific validation is limited by the small size, short duration, and sometimes low quality of available studies. The European Food Safety Authority (EFSA) and US FDA recognize steviol glycosides as safe for use as sweeteners, but do not endorse them specifically for treating or preventing Metabolic Syndrome. Thus, while there is a scientific rationale and some preliminary evidence, the overall support remains weak, and steviol glycosides should not be considered a primary therapeutic intervention for Metabolic Syndrome.

More about Steviol glycoside (unspecified)
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Steviol glycoside (unspecified)

Products containing Steviol glycoside (unspecified)